

Supplemental Table 1: Univariate associations between baseline factors and treatment response (<i>N</i> = 125)					
Factor	Treatment response, n (%)*				P value
	Total	No response (n = 32)	Partial remission (n = 35)	Complete remission (n = 58)	
ANA positivity					0.575
No	14 (11.1)	5 (15.6)	5 (14.3)	4 (6.9)	
Yes	111 (88.1)	27 (84.4)	30 (85.7)	54 (93.1)	
Anti-dsDNA positivity					0.834
No	69 (54.8)	19 (59.4)	21 (60.0)	29 (50.0)	
Yes	46 (36.8)	12 (37.5)	11 (31.4)	23 (39.7)	
Anemia					0.947
No	27 (21.4)	8 (25.0)	7 (20.0)	12 (20.7)	
Yes	97 (77.0)	24 (75.0)	28 (80.0)	45 (77.6)	
Leukopenia					0.380
No	108 (85.7)	29 (90.6)	33 (94.3)	46 (79.3)	
Yes	16 (12.7)	3 (9.4)	2 (5.7)	11 (19.0)	
Thrombocytopenia					0.947
No	106 (84.1)	27 (84.4)	30 (90.9)	49 (84.5)	
Yes	14 (11.1)	4 (12.5)	3 (9.1)	7 (12.1)	
Induction therapy					0.834
MMF	86 (68.2)	23 (71.9)	22 (62.9)	41 (70.7)	
CYC	19 (15.1)	4 (12.5)	8 (22.9)	7 (12.1)	
AZA	16 (12.7)	3 (9.4)	4 (11.4)	9 (15.5)	
CNI	4 (3.2)	2 (6.3)	1 (2.9)	1 (1.7)	
Maintenance therapy					0.510
MMF	71 (56.3)	22 (68.8)	22 (62.9)	27 (46.6)	
AZA	17 (13.5)	4 (12.5)	5 (14.3)	8 (13.8)	
CNI	5 (4.0)	1 (3.1)	2 (5.7)	2 (3.4)	
MMF and CNI	32 (25.4)	5 (15.6)	6 (17.1)	21 (36.2)	

Supplementary Table 2 Treatment response by ISN/RPS histological class (*N* = 125)

Class	N	CR n (%)	PR n (%)	NR n (%)
III	18	12 (66.7)	2 (11.1)	4 (22.2)
IV	58	26 (44.8)	13 (22.4)	19 (32.8)
V	25	8 (32.0)	11 (44.0)	6 (24.0)
Mixed III/IV+V	10	4 (40.0)	3 (30.0)	3 (30.0)

Supplemental table 3 Multivariable logistic regression predictors of complete remission (*N* = 125)

Variable	Adjusted OR	95% CI	P value
Age at biopsy (per year)	1	0.96 - 1.04	0.9
Male sex (vs female)	3.47	1.03 - 12.12	0.04
ISN/RPS Class III (vs IV)	0.99	0.20 - 4.33	0.9
ISN/RPS Class V (vs IV)	0.6	0.12 - 2.56	0.5

ISN/RPS Other class (vs IV)	0.48	0.11 - 1.82	0.3
CYC induction (vs MMF)	0.41	0.09 - 1.63	0.2
AZA induction (vs MMF)	0.98	0.16 - 4.85	0.9
Other induction (vs MMF)	1.62	0.13 - 21.17	0.7
Serum creatinine at biopsy (per mg/dL)	1.57	0.77 - 3.34	0.2
uPCR at biopsy (per unit)	1.08	0.97 - 1.22	0.2
Low C3 at diagnosis (vs normal)	0.72	0.24 - 2.21	0.6
Hypertension at biopsy	2.78	0.77 - 12.44	0.1
AKI at biopsy	0.73	0.17 - 2.84	0.7
Late-onset LN (>2 y vs ≤2 y)	1.46	0.47 - 4.49	0.5

Supplemental table 4 Multivariable Cox regression analysis of overall survival (*N* = 125)

Variable	Adjusted HR	95% CI	P value
Non-responder (vs CR or PR)	2.68	0.94 - 7.66	0.07
Age at biopsy (per year)	1.01	0.97 - 1.05	0.7

Supplementary Table 5 Comparison of cyclophosphamide versus mycophenolate mofetil induction for complete remission

Variable	Adjusted HR	95% CI	P value
CYC induction (vs MMF)	0.36	0.09 - 1.41	0.1
Age at biopsy (per year)	0.96	0.90 - 1.02	0.2
Serum creatinine at biopsy (per mg/dL)	3.33	1.98 - 5.59	<0.001
Low C3 at diagnosis (vs normal)	1.7	0.44 - 6.61	0.4

Supplementary Table 6 Comparison of cyclophosphamide versus mycophenolate mofetil induction for renal survival

Variable	Adjusted OR	95% CI	P value
CYC induction (vs MMF)	0.44	0.12 - 1.47	0.2
Age at biopsy (per year)	1.01	0.96 - 1.05	0.8
Serum creatinine at biopsy (per mg/dL)	0.44	0.21 - 0.80	0.01
Low C3 at diagnosis (vs normal)	2.9	0.80 - 12.26	0.1